Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 3Lymphoma 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lymphoma, Follicular 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor and Lymphoma Malignancies 1Advanced Solid Neoplasms 1

Interventions

Paclitaxel 326Carboplatin 318Bevacizumab 167Gemcitabine 106pembrolizumab 101liposomal doxorubicin 100Cyclophosphamide 96Topotecan 93Cisplatin 89olaparib 86niraparib 60Docetaxel 56Taxes 52Doxorubicin 50Drug Therapy 42fludarabine 40Filgrastim 39Nivolumab 37Etoposide 32Specimen Handling 31Magnetic Resonance Spectroscopy 29Immunoglobulin G 27Disulfides 27Peripheral Blood Stem Cell Transplantation 26Albumin-Bound Paclitaxel 25durvalumab 24aldesleukin 24Hyperthermic Intraperitoneal Chemotherapy 24Oxaliplatin 23Biopsy 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ovarian Neoplasms × TAK-659 × Clear all
NCT03756818 2023-02-28

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
52 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡